HS6ST3

Summary

HS6ST3 (heparan sulfate 6-O-sulfotransferase 3, HGNC:19134) is a protein-coding gene on chromosome 13q32.1, encoding Heparan-sulfate 6-O-sulfotransferase 3 (Q8IZP7). 6-O-sulfation enzyme which catalyzes the transfer of sulfate from 3’-phosphoadenosine 5’-phosphosulfate (PAPS) to position 6 of the N-sulfoglucosamine residue (GlcNS) of heparan sulfate.

Heparan sulfate (HS) sulfotransferases, such as HS6ST3, modify HS to generate structures required for interactions between HS and a variety of proteins. These interactions are implicated in proliferation and differentiation, adhesion, migration, inflammation, blood coagulation, and other diverse processes (Habuchi et al., 2000 [PubMed 10644753]).

Source: NCBI Gene 266722 — RefSeq curated summary.

At a glance

• GWAS associations: 16
• Clinical variants (ClinVar): 93 total
• MANE Select transcript: NM_153456

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19134
Approved symbol	HS6ST3
Name	heparan sulfate 6-O-sulfotransferase 3
Location	13q32.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000185352
Ensembl biotype	protein_coding
OMIM	609401
Entrez	266722

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000376705

RefSeq mRNA: 1 — MANE Select: NM_153456 NM_153456

CCDS: CCDS9481

Canonical transcript exons

ENST00000376705 — 2 exons

Exon	Start	End
ENSE00001471420	96832490	96839562
ENSE00001471427	96090107	96091569

Expression profiles

Bgee: expression breadth ubiquitous, 183 present calls, max score 96.56.

FANTOM5 (CAGE): breadth broad, TPM avg 2.0579 / max 115.0223, expressed in 361 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
135703	0.9342	258
135704	0.7267	219
135705	0.1149	70
135707	0.1081	58
135706	0.0981	56
135708	0.0760	39

Top tissues by expression

246 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lateral nuclear group of thalamus	UBERON:0002736	96.56	gold quality
middle temporal gyrus	UBERON:0002771	94.59	gold quality
parietal lobe	UBERON:0001872	94.44	gold quality
postcentral gyrus	UBERON:0002581	94.01	gold quality
superior frontal gyrus	UBERON:0002661	93.55	gold quality
entorhinal cortex	UBERON:0002728	93.15	gold quality
Brodmann (1909) area 23	UBERON:0013554	91.98	gold quality
lateral globus pallidus	UBERON:0002476	91.25	gold quality
endothelial cell	CL:0000115	90.90	gold quality
occipital lobe	UBERON:0002021	89.54	gold quality
ventral tegmental area	UBERON:0002691	89.20	gold quality
primary visual cortex	UBERON:0002436	87.89	gold quality
superior vestibular nucleus	UBERON:0007227	86.55	gold quality
Brodmann (1909) area 46	UBERON:0006483	86.00	gold quality
buccal mucosa cell	CL:0002336	85.93	gold quality
medulla oblongata	UBERON:0001896	85.93	gold quality
cerebellar vermis	UBERON:0004720	85.76	gold quality
frontal cortex	UBERON:0001870	85.74	gold quality
prefrontal cortex	UBERON:0000451	85.65	gold quality
dorsal plus ventral thalamus	UBERON:0001897	85.53	gold quality
pancreatic ductal cell	CL:0002079	85.49	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	85.12	gold quality
substantia nigra pars reticulata	UBERON:0001966	85.08	gold quality
cerebral cortex	UBERON:0000956	84.99	gold quality
neocortex	UBERON:0001950	84.68	gold quality
cardiac muscle of right atrium	UBERON:0003379	84.13	gold quality
substantia nigra pars compacta	UBERON:0001965	84.10	gold quality
Ammon’s horn	UBERON:0001954	83.69	gold quality
Brodmann (1909) area 9	UBERON:0013540	82.83	gold quality
temporal lobe	UBERON:0001871	82.66	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	2796.47
E-GEOD-180759	yes	1938.61
E-HCAD-25	yes	1845.03
E-MTAB-7249	yes	54.69
E-CURD-119	yes	40.23
E-ANND-3	yes	5.55

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

196 targeting HS6ST3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-1250-3P	99.96	70.04	4038

Literature-anchored findings (GeneRIF, showing 2)

• Single-nucleotide polymorphisms within the HS6ST3 gene are associated with obesity and triglyceride levels. [Meta-analysis] (PMID:24371161)
• Silencing HS6ST3 diminished tumor cell growth and progression in breast cancer cells. Silencing HS6ST3 down-regulated IGF1R and up-regulated XAF1. (PMID:28017727)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	hs6st3b	ENSDARG00000069500
danio_rerio	hs6st3a	ENSDARG00000071217
mus_musculus	Hs6st3	ENSMUSG00000053465
rattus_norvegicus	Hs6st3	ENSRNOG00000037886
drosophila_melanogaster	Hs6st	FBGN0038755
caenorhabditis_elegans		WBGENE00002031

Paralogs (2): HS6ST1 (ENSG00000136720), HS6ST2 (ENSG00000171004)

Protein

Protein identifiers

Heparan-sulfate 6-O-sulfotransferase 3 — Q8IZP7 (reviewed: Q8IZP7)

All UniProt accessions (1): Q8IZP7

UniProt curated annotations — full annotation on UniProt →

Function. 6-O-sulfation enzyme which catalyzes the transfer of sulfate from 3’-phosphoadenosine 5’-phosphosulfate (PAPS) to position 6 of the N-sulfoglucosamine residue (GlcNS) of heparan sulfate.

Subcellular location. Membrane.

Similarity. Belongs to the sulfotransferase 6 family.

RefSeq proteins (1): NP_703157* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005331	Sulfotransferase	Family
IPR010635	Heparan_SO4-6-sulfoTrfase	Family
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF03567

Catalyzed reactions (Rhea), 1 shown:

• alpha-D-glucosaminyl-heparan sulfate + 3’-phosphoadenylyl sulfate = 6-sulfo-alpha-D-glucosaminyl-heparan sulfate + adenosine 3’,5’-bisphosphate + H(+) (RHEA:56604)

UniProt features (31 total): binding site 11, glycosylation site 6, compositionally biased region 5, topological domain 2, region of interest 2, chain 1, active site 1, transmembrane region 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IZP7-F1	81.20	0.63

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 209 (proton acceptor)

Ligand- & substrate-binding residues (11): 152–160; 182–183; 199; 204; 209; 245; 253; 257; 264; 377–379; 383–384

Glycosylation sites (6): 117, 128, 231, 324, 329, 380

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-2022928	HS-GAG biosynthesis

MSigDB gene sets: 141 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, E2F_Q4, BENPORATH_ES_WITH_H3K27ME3, E2F4DP1_01, PEREZ_TP63_TARGETS, AREB6_01, GGGTGGRR_PAX4_03, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, E2F1DP1_01, E2F_Q3, E2F1DP2_01, WANG_LMO4_TARGETS_DN, GOBP_HEPARAN_SULFATE_PROTEOGLYCAN_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, GGCKCATGS_UNKNOWN

GO Biological Process (1): heparan sulfate proteoglycan biosynthetic process (GO:0015012)

GO Molecular Function (3): heparan sulfate 6-sulfotransferase activity (GO:0017095), sulfotransferase activity (GO:0008146), transferase activity (GO:0016740)

GO Cellular Component (2): Golgi apparatus (GO:0005794), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Heparan sulfate/heparin (HS-GAG) metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
proteoglycan biosynthetic process	1
heparan sulfate proteoglycan metabolic process	1
protein O-linked glycosylation via xylose	1
heparan sulfate sulfotransferase activity	1
transferase activity, transferring sulphur-containing groups	1
catalytic activity	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

774 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HS6ST3	HS2ST1	Q7LGA3	659
HS6ST3	HS3ST6	Q96QI5	635
HS6ST3	NDST4	Q9H3R1	628
HS6ST3	NDST2	P52849	627
HS6ST3	HS3ST1	O14792	620
HS6ST3	GLCE	O94923	618
HS6ST3	HS3ST5	Q8IZT8	606
HS6ST3	NDST3	O95803	570
HS6ST3	K7EP71	K7EP71	550
HS6ST3	HS3ST3B1	Q9Y662	547
HS6ST3	FAM162B	Q5T6X4	544
HS6ST3	HS3ST4	Q9Y661	543
HS6ST3	NDST1	P52848	519
HS6ST3	HS3ST3A1	Q9Y663	518
HS6ST3	SULF2	Q8IWU5	503

IntAct

6 interactions, top by confidence:

A	B	Type	Score
	PLOD2	psi-mi:“MI:0914”(association)	0.350
NOS1	C1orf226	psi-mi:“MI:0914”(association)	0.350
HS6ST3	HS6ST1	psi-mi:“MI:0914”(association)	0.350
DEFB116	SRC	psi-mi:“MI:0914”(association)	0.350
DOCK3	HS6ST3	psi-mi:“MI:0914”(association)	0.350

BioGRID (9): HS6ST3 (Affinity Capture-MS), HS6ST3 (Affinity Capture-RNA), HS6ST3 (Affinity Capture-MS), IDE (Affinity Capture-MS), HS6ST3 (Affinity Capture-MS), HS6ST1 (Affinity Capture-MS), HS6ST3 (Affinity Capture-MS), HS6ST3 (Positive Genetic), HS6ST3 (Affinity Capture-MS)

ESM2 similar proteins: A0A8C2LVE3, A0MGZ5, A0MGZ7, A4IID1, A5D7I4, A9X1C8, O08889, O12971, O60243, O93336, O97583, P0DJQ9, P52849, P52850, P61642, P69478, P97464, Q16394, Q56UJ5, Q5IGR7, Q5IGR8, Q5R621, Q5RBC3, Q5U4X8, Q6GQK9, Q6KFX9, Q6ZXD2, Q76KB1, Q76KB2, Q7LFX5, Q7LGA3, Q7T3S3, Q800H9, Q80UW0, Q86V40, Q8CHI9, Q8IZP7, Q8R3H7, Q91XQ5, Q91ZB4

Diamond homologs: A0MGZ5, A0MGZ7, O60243, Q56UJ5, Q76KB2, Q76LW2, Q800H9, Q80UW0, Q8IZP7, Q91ZB4, Q96MM7, Q9QYK4, Q9QYK5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

93 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	88
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

4601 predictions. Top by Δscore:

Variant	Effect	Δscore
13:96091568:AGGTA:A	donor_loss	1.0000
13:96091569:GGTAC:G	donor_loss	1.0000
13:96091570:G:GA	donor_loss	1.0000
13:96367760:G:GT	donor_gain	1.0000
13:96488146:C:A	acceptor_gain	1.0000
13:96511240:C:CG	donor_gain	1.0000
13:96511240:C:G	donor_gain	1.0000
13:96091571:T:A	donor_loss	0.9900
13:96116178:G:GT	donor_gain	0.9900
13:96147435:A:AG	donor_gain	0.9900
13:96187846:G:GA	donor_gain	0.9900
13:96211705:G:T	donor_gain	0.9900
13:96405561:A:G	donor_gain	0.9900
13:96488147:G:A	acceptor_gain	0.9900
13:96488151:T:A	acceptor_gain	0.9900
13:96488152:G:A	acceptor_gain	0.9900
13:96511236:GAAAC:G	donor_gain	0.9900
13:96573510:G:GT	donor_gain	0.9900
13:96116206:GCAT:G	donor_gain	0.9800
13:96187848:T:TA	donor_gain	0.9800
13:96187849:A:AA	donor_gain	0.9800
13:96247180:T:TA	acceptor_gain	0.9800
13:96341169:G:GA	donor_gain	0.9800
13:96405440:A:T	donor_gain	0.9800
13:96405558:GACA:G	donor_gain	0.9800
13:96405561:A:AG	donor_gain	0.9800
13:96569295:A:T	donor_gain	0.9800
13:96573485:G:GT	donor_gain	0.9800
13:96573507:G:GT	donor_gain	0.9800
13:96091570:G:GG	donor_gain	0.9700

AlphaMissense

3131 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:96091281:T:C	F140S	1.000
13:96091299:A:T	D146V	1.000
13:96091308:T:A	V149E	1.000
13:96091310:T:C	F150L	1.000
13:96091311:T:C	F150S	1.000
13:96091312:C:A	F150L	1.000
13:96091312:C:G	F150L	1.000
13:96091314:T:A	L151H	1.000
13:96091314:T:C	L151P	1.000
13:96091316:C:A	H152N	1.000
13:96091316:C:G	H152D	1.000
13:96091316:C:T	H152Y	1.000
13:96091317:A:G	H152R	1.000
13:96091317:A:T	H152L	1.000
13:96091318:C:A	H152Q	1.000
13:96091318:C:G	H152Q	1.000
13:96091324:G:C	Q154H	1.000
13:96091324:G:T	Q154H	1.000
13:96091325:A:C	K155Q	1.000
13:96091325:A:G	K155E	1.000
13:96091326:A:C	K155T	1.000
13:96091326:A:T	K155M	1.000
13:96091327:G:C	K155N	1.000
13:96091327:G:T	K155N	1.000
13:96091328:A:C	T156P	1.000
13:96091329:C:A	T156K	1.000
13:96091331:G:A	G157R	1.000
13:96091331:G:C	G157R	1.000
13:96091331:G:T	G157W	1.000
13:96091332:G:A	G157E	1.000

dbSNP variants (sampled 300 via entrez): RS1000008237 (13:96400755 T>C), RS1000009996 (13:96456645 G>T), RS1000010003 (13:96622836 A>G), RS1000012370 (13:96134694 C>G), RS1000015041 (13:96262692 G>A), RS1000030682 (13:96429736 A>C), RS1000031163 (13:96814248 C>A), RS1000032543 (13:96514606 C>T), RS1000042197 (13:96743364 G>A), RS1000042248 (13:96390816 T>C,G), RS1000047537 (13:96172848 AAAT>A), RS1000048553 (13:96688756 G>A), RS1000056346 (13:96492687 C>T), RS1000062224 (13:96179116 G>C), RS1000064943 (13:96134333 T>C)

Disease associations

OMIM: gene MIM:609401 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST000966_8	Diabetic retinopathy	5.000000e-11
GCST001953_45	Obesity	1.000000e-08
GCST002386_24	Cognitive function	7.000000e-06
GCST002783_248	Body mass index	1.000000e-06
GCST002783_427	Body mass index	4.000000e-07
GCST002783_577	Body mass index	2.000000e-06
GCST004904_172	Body mass index	3.000000e-08
GCST007327_150	Smoking status (ever vs never smokers)	6.000000e-09
GCST007335_26	Age at first sexual intercourse	3.000000e-08
GCST009269_15	Dental caries (decayed and filled deciduous teeth)	4.000000e-06
GCST009844_5	Creativity	8.000000e-06
GCST010002_193	Refractive error	6.000000e-09
GCST010988_474	Adult body size	5.000000e-11
GCST011140_4	Glucagon levels in response to oral glucose tolerance test (decremental area under the curve for 0-30 minutes)	3.000000e-06
GCST012090_46	Major depressive disorder (MTAG)	3.000000e-08
GCST012323_3	Total cholesterol levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	2.000000e-08

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0003925	cognition
EFO:0004340	body mass index
EFO:0004318	smoking behavior
EFO:0009749	age at first sexual intercourse measurement
EFO:0010650	creativity measurement
EFO:0008463	glucagon measurement
EFO:0004574	total cholesterol measurement
EFO:0005658	response to selective serotonin reuptake inhibitor

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs118042719	HS6ST3		0.00	0

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, decreases methylation, affects cotreatment	7
Benzo(a)pyrene	increases methylation, affects expression, affects methylation, decreases expression	5
Aflatoxin B1	decreases expression, decreases methylation, increases methylation	4
lasiocarpine	decreases expression	2
methyleugenol	decreases expression	2
N-Nitrosopyrrolidine	decreases expression	2
aflatoxin B2	decreases methylation	1
entinostat	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
Grape Seed Proanthocyanidins	increases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	decreases expression	1
Catechin	increases expression, affects cotreatment	1
Cisplatin	decreases expression	1
Copper	affects cotreatment, decreases expression	1
Methotrexate	decreases expression	1
Nickel	decreases expression	1
Tretinoin	increases expression	1
Antirheumatic Agents	decreases expression	1
Permethrin	decreases expression	1

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists